Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

NCT04149821 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT04149821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04149821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Terminated
Start date
February 10, 2021
Completion date
June 9, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, cll progression, cll/sll